| Company/Division name | Neogene Therapeutics |
| Parent company | Barrick Gold Corporation |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
| Year reshoring announced: | 2022 |
| Year reshoring implemented or to be implemented: | 2024 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | Canada |
| City reshored to: | Elko |
| State(s) reshored to: | NV |
| If relevant, work nearshored to: | - |
| Industry(ies): | Computer & Electronic Products |
| Product(s) reshored | Solar power plant |
| What non-domestic negative factors made offshoring less attractive? | Green considerations |
| What domestic positive factors made reshoring more attractive? | , NGM committed to 20% carbon reduction by 2025 |
